Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR; Assessment of Lescol in Renal Transplantation Study Investigators. Fellström B, et al. Among authors: olsson ag. Kidney Int. 2004 Oct;66(4):1549-55. doi: 10.1111/j.1523-1755.2004.00919.x. Kidney Int. 2004. PMID: 15458450 Free article. Clinical Trial.
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Holdaas H, et al. Among authors: olsson ag. Lancet. 2003 Jun 14;361(9374):2024-31. doi: 10.1016/S0140-6736(03)13638-0. Lancet. 2003. PMID: 12814712 Clinical Trial.
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study.
Jardine AG, Holdaas H, Fellström B, Cole E, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambühl P, Olsson AG, Holme I, Fauchald P, Gimpelwicz C, Pedersen TR; ALERT Study Investigators. Jardine AG, et al. Among authors: olsson ag. Am J Transplant. 2004 Jun;4(6):988-95. doi: 10.1111/j.1600-6143.2004.00445.x. Am J Transplant. 2004. PMID: 15147434 Free article. Clinical Trial.
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial.
Fellström B, Holdaas H, Jardine AG, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Staffler B, Pedersen TR; Assessment of Lescol in Renal Transplantation Study Investigators. Fellström B, et al. Among authors: olsson ag. Transplantation. 2005 Jan 27;79(2):205-12. doi: 10.1097/01.tp.0000147338.34323.12. Transplantation. 2005. PMID: 15665769 Clinical Trial.
Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data.
Holdaas H, Fellström B, Holme I, Nyberg G, Fauchald P, Jardine A, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Weinreich T, Olsson AG, Pedersen TR, Benghozi R, Hartmann A; ALERT Study Group. Assessment of Lescol in Renal Transplantation. Holdaas H, et al. Among authors: olsson ag. J Cardiovasc Risk. 2001 Apr;8(2):63-71. doi: 10.1177/174182670100800202. J Cardiovasc Risk. 2001. PMID: 11324372 Clinical Trial.
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.
Holdaas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Grönhagen-Riska C, Neumayer HH, Maes B, Ambühl P, Hartmann A, Staffler B, Jardine AG; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Holdaas H, et al. Among authors: olsson ag. Am J Transplant. 2005 Dec;5(12):2929-36. doi: 10.1111/j.1600-6143.2005.01105.x. Am J Transplant. 2005. PMID: 16303007 Free article. Clinical Trial.
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group. Holme I, et al. Among authors: olsson ag. Ann Med. 2008;40(6):456-64. doi: 10.1080/07853890801964955. Ann Med. 2008. PMID: 19160529 Clinical Trial.
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.
Olsson AG, Lindahl C, Holme I, Fayyad R, Faergeman O, Kastelein JJ, Tikkanen MJ, Larsen ML, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Olsson AG, et al. Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):262-9. doi: 10.1177/1741826710389391. Epub 2011 Feb 8. Eur J Cardiovasc Prev Rehabil. 2011. PMID: 21450674 Clinical Trial.
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, Kastelein JJ, Holme I, Pedersen TR; IDEAL Investigators. Tikkanen MJ, et al. Among authors: olsson ag. Int J Cardiol. 2013 Oct 9;168(4):3846-52. doi: 10.1016/j.ijcard.2013.06.024. Epub 2013 Aug 31. Int J Cardiol. 2013. PMID: 24001698 Clinical Trial.
314 results